Experimental Drugs for the Treatment of Hepatitis D
Lisa Sandmann, Markus Cornberg
Abstract
Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.
Topics & Concepts
Hepatocellular carcinomaMedicinePegylated interferonHepatitis DChronic hepatitisInterferonAntiviral treatmentHepatitis CViral hepatitisLiver diseaseVirologyHepatitisImmunologyVirusInternal medicineRibavirinHepatitis B virusHBsAgHepatitis B Virus StudiesHepatitis C virus researchHepatitis Viruses Studies and Epidemiology